UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Cardiovascular Drug Development

Journal of the American College of Cardiology, 2015-04, Vol.65 (15), p.1567-1582

2015

Volltextzugriff (PDF)

Rivaroxaban in Peripheral Artery Disease after Revascularization. Reply

The New England journal of medicine, 2020-11, Vol.383 (21), p.2090-2091

2020

Volltextzugriff (PDF)

PCSK9 Inhibitors: Mechanisms of Action, Metabolic Effects, and Clinical Outcomes

Annual review of medicine, 2018-01, Vol.69 (1), p.133-145

2018

Volltextzugriff (PDF)

Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC)

Journal of the American College of Cardiology, 2015-03, Vol.65 (9), p.931-941

2015

Volltextzugriff (PDF)

Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety

Circulation (New York, N.Y.), 2020-12, Vol.142 (23), p.2219-2230

2020

Volltextzugriff (PDF)

Progress in the prevention and treatment of atherosclerotic cardiovascular disease: two steps forward, one step back

European heart journal, 2020-05, Vol.41 (17), p.1650-1652

2020

Volltextzugriff (PDF)

The Treatment Gap in Peripheral Artery Disease

Journal of the American College of Cardiology, 2017-05, Vol.69 (18), p.2301-2303

2017

Volltextzugriff (PDF)

Long-Term Outcomes and Associations With Major Adverse Limb Events After Peripheral Artery Revascularization

Journal of the American College of Cardiology, 2020-02, Vol.75 (5), p.498-508

2020

Volltextzugriff (PDF)

Obituary – John A Dormandy (5.3.1937–26.4.2019)

European journal of vascular and endovascular surgery, 2019-09, Vol.58 (3), p.466-466

2019

Volltextzugriff (PDF)

Major Adverse Limb Events and 1-Year Outcomes After Peripheral Artery Revascularization

Journal of the American College of Cardiology, 2018-08, Vol.72 (9), p.999-1011

2018

Volltextzugriff (PDF)

An Update on Methods for Revascularization and Expansion of the TASC Lesion Classification to Include Below-the-Knee Arteries: A Supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)

Journal of endovascular therapy, 2015-10, Vol.22 (5), p.663-677

2015

Volltextzugriff (PDF)

The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications

Thrombosis and haemostasis, 2016-06, Vol.115 (6), p.1240-1248

2016

Volltextzugriff (PDF)

Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: A meta-analysis of randomized trials

The American heart journal, 2011-07, Vol.162 (1), p.115-124.e2

2011

Volltextzugriff (PDF)

The treadmill is a better functional test than the 6-minute walk test in therapeutic trials of patients with peripheral artery disease

Circulation (New York, N.Y.), 2014-07, Vol.130 (1), p.69-78

2014

Volltextzugriff (PDF)

An Update on Methods for Revascularization and Expansion of the TASC Lesion Classification to Include Below-the-Knee Arteries: A Supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)

Vascular medicine (London, England), 2015-10, Vol.20 (5), p.465-478

2015

Volltextzugriff (PDF)

Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study

The American heart journal, 2021-05, Vol.235, p.12-23

2021

Volltextzugriff (PDF)

Aspirin Monotherapy Should Not Be Recommended for Cardioprotection in Patients With Symptomatic Peripheral Artery Disease

Circulation (New York, N.Y.), 2017-08, Vol.136 (9), p.785-786

2017

Volltextzugriff (PDF)

Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients

Journal of the American College of Cardiology, 2020-06, Vol.75 (25), p.3140-3147

2020

Volltextzugriff (PDF)

Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial

Journal of the American College of Cardiology, 2021-07, Vol.78 (4), p.317-326

2021

Volltextzugriff (PDF)

Omega-3 fatty acids for intermittent claudication

Cochrane database of systematic reviews, 2013-07 (7), p.CD003833-CD003833

2013

Volltextzugriff (PDF)

Effectiveness of Blood Lipid Management in Patients With Peripheral Artery Disease

Journal of the American College of Cardiology, 2021-06, Vol.77 (24), p.3016-3027

2021

Volltextzugriff (PDF)

Cardiovascular drug development: is it dead or just hibernating?

Journal of the American College of Cardiology, 2015-04, Vol.65 (15), p.1567-1582

2015

Volltextzugriff (PDF)

Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial

Circulation (New York, N.Y.), 2021-10, Vol.144 (14), p.1104-1116

2021

Volltextzugriff (PDF)

A call to action: women and peripheral artery disease: a scientific statement from the American Heart Association

Circulation (New York, N.Y.), 2012-03, Vol.125 (11), p.1449-1472

2012

Volltextzugriff (PDF)

Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease: The EUCLID Trial

Journal of the American College of Cardiology, 2018-12, Vol.72 (25), p.3274-3284

2018

Volltextzugriff (PDF)

26 – 50 von 576

Suche als RSS-Feed

Aktive Filter

ThemaBlood And Lymphatic Vessels

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(505)
Mit Volltextzugriff
(458)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(575)

Erscheinungsjahr

n.n

Thema

Science & Technology
(350)
Life Sciences & Biomedicine
(343)
Humans
(306)
Male
(162)
Female
(159)
Cardiovascular System & Cardiology
(158)
Middle Aged
(114)
Biological And Medical Sciences
(105)
Aged
(97)
Cardiac & Cardiovascular Systems
(96)
Peripheral Vascular Disease
(96)
Medical Sciences
(85)
Risk Factors
(83)
Adult
(66)
Treatment Outcome
(62)
Peripheral Artery Disease
(57)
Surgery
(49)
General & Internal Medicine
(42)
Cardiovascular Disease
(41)
Medicine, General & Internal
(41)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Free E-Journal (出版社公開部分のみ）
(344)
MEDLINE
(332)
Journals@Ovid Full Text
(324)
Ingenta.com
(279)
Elsevier ScienceDirect Journals Complete
(166)
Publisher or Other Site
(161)
IngentaConnect Journals
(131)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(64)
Wiley Online Library All Journals
(56)
SAGE Journals
(48)
Wiley Online Library
(34)
JSTOR
(21)
2022 ECC(Springer)
(18)
Oxford Journals
(16)
eBooks on EBSCOhost
(16)
Ebook Central Perpetual and DDA
(14)
Nature_系列刊
(14)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(13)
Oxford Journals 2020 Medicine
(10)
Nexis Uni
(10)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Cardiovascular Drug Development

Rivaroxaban in Peripheral Artery Disease after Revascularization. Reply

PCSK9 Inhibitors: Mechanisms of Action, Metabolic Effects, and Clinical Outcomes

Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC)

Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety

Progress in the prevention and treatment of atherosclerotic cardiovascular disease: two steps forward, one step back

The Treatment Gap in Peripheral Artery Disease

Long-Term Outcomes and Associations With Major Adverse Limb Events After Peripheral Artery Revascularization

Obituary – John A Dormandy (5.3.1937–26.4.2019)

Major Adverse Limb Events and 1-Year Outcomes After Peripheral Artery Revascularization

An Update on Methods for Revascularization and Expansion of the TASC Lesion Classification to Include Below-the-Knee Arteries: A Supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)

The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications

Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: A meta-analysis of randomized trials

The treadmill is a better functional test than the 6-minute walk test in therapeutic trials of patients with peripheral artery disease

An Update on Methods for Revascularization and Expansion of the TASC Lesion Classification to Include Below-the-Knee Arteries: A Supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)

Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study

Aspirin Monotherapy Should Not Be Recommended for Cardioprotection in Patients With Symptomatic Peripheral Artery Disease

Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients

Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial

Omega-3 fatty acids for intermittent claudication

Effectiveness of Blood Lipid Management in Patients With Peripheral Artery Disease

Cardiovascular drug development: is it dead or just hibernating?

Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial

A call to action: women and peripheral artery disease: a scientific statement from the American Heart Association

Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease: The EUCLID Trial

Aktive Filter

Suchergebnisse filtern